Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you recommend endocrine therapy in DCIS with a low burden of ER expression (eg, 10-15% positive)?
Related Questions
Would you omit radiation for an elderly woman with bilateral breast cancers (both early-stage disease and ER+/PR+/HER2 negative) who otherwise meets the criteria for endocrine therapy alone?
How do you approach early-stage breast cancer patients who are asking for ctDNA or tumor marker surveillance (or previously receiving these with another provider) when these are not part of the NCCN or ASCO guidelines?
How do you treat high-risk inflammatory TNBC diagnosed in the first trimester of pregnancy who underwent surgery?
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
What are your top takeaways in Breast Cancer from ASCO 2024?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
What modifications, if any, will you make for your use of dose dense taxane chemotherapy in early stage breast cancer with the end-of-study PANTHER results?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
